Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.39 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.39 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28263698 | 0.82 | CA1 (0.46) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL10729798 | 0.82 | CA1 (0.46) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL14514287 | 0.77 | SMN1; SMN2 (0.54) | CA1DAOALDH1A1LMNACHEK1 | |
| SCHEMBL27317367 | 0.77 | CA1 (0.42) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL25136295 | 0.76 | CA1 (0.44) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL27661275 | 0.76 | ALDH1A1 (0.45) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL18412738 | 0.74 | DAO (0.39) | CA1DAOALDH1A1LMNAGPR84 | |
| SCHEMBL11471145 | 0.74 | DAO (0.39) | CA1DAOALDH1A1LMNACYP1A2 | |
| SCHEMBL3060311 | 0.73 | GPR84 (0.46) | DAOGPR84 | |
| SCHEMBL7436503 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957328-A | Polynucleotide and use thereof | 斯特兰德生物科技公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230174505-A1 | DERIVATIZED BENZIMIDAZOLE COMPOUNDS, THEIR SALTS, THEIR COMPLEXES, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM FOR ANTIGERIATRIC ACTIONS | FARBER BORIS (US) | 2023-06-08 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10590158-B2 | Total synthesis of shishijimicin A and analogs thereof | WILLIAM MARSH RICE UNIVERSITY (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| EP-2958919-B1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | DUKE UNIVERSITY | 2016-08-11 | — | — | US | disclosed |
| US-9006226-B2 | Dihydropteridinones I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006226-B2 | Dihydropteridinones I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| WO-2014127815-A1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-28 | — | — | WO | disclosed |
| US-20130225549-A1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225549-A1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-8288381-B2 | N-9 substituted purine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-4014677-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229811-A1 | TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER | AR, FSHR, ESRRB | CA1 3060/4885DAO 3221/4885ALDH1A1 2136/4885 |
| US-10590158-B2 | Total synthesis of shishijimicin A and analogs thereof | SYK, UGT1A7, FCGRT | CA1 2591/4885DAO 994/4885ALDH1A1 809/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | CA1 4416/4885DAO 4165/4885ALDH1A1 3413/4885 |
| US-20130225549-A1 | DIHYDROPTERIDINONES I | BACE1, APP, BACE2 | CA1 1329/4885DAO 2964/4885ALDH1A1 2968/4885 |
| US-20230174505-A1 | DERIVATIZED BENZIMIDAZOLE COMPOUNDS, THEIR SALTS, THEIR COMPLEXES, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM FOR ANTIGERIATRIC ACTIONS | PPARG, AGER, PPARD | CA1 4851/4885DAO 2306/4885ALDH1A1 1165/4885 |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | TRIM33, TRIM28, TRIM4 | CA1 4391/4885DAO 4312/4885ALDH1A1 3246/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | CA1 2442/4885DAO 4117/4885ALDH1A1 3317/4885 |
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX7, P2RY1, PNP | CA1 3263/4885DAO 527/4885ALDH1A1 349/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | CA1 3820/4885DAO 3310/4885ALDH1A1 1655/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | CA1 4416/4885DAO 4165/4885ALDH1A1 3413/4885 |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, OAT | CA1 1086/4885DAO 1899/4885ALDH1A1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.